Disclaimer: As always, I have not been compensated in any way, shape, or form to write this “blog” or Tweet about the company. I do admit to owning shares, which I bought at the end of September and added along the way. While I have no intention of selling shares at any particular time, I reserve the right to sell when I want without notice. Obviously, right? This is not pumping. It’s simply relaying some basic due diligence to help you more easily find the verifiable resources.
RDGL (Vivos, Inc.) caught my attention after the September 26th news release titled “First Successful Treatment of Canine Sarcoma using IsoPet® to be Presented at Veterinary Cancer Society Conference“.
Vivos Inc, a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in humans and animals, is pleased to report several significant outcomes after its signature product, IsoPet®, was used to treat a hind-leg soft-tissue sarcoma in a Sheltie at the University of Missouri Veterinary Health Center in Columbia, Missouri.
My first step was to head to the University of Missouri Veterinary Health Center website to see if they mention RadioGel, IsoPet, etc. Sure enough, they do on their “Current Clinical Trials” section under the listing “ISOPET Yttrium STS Study”.
Veterinary oncologist, Dr. Charles Maitz, reported that the treatment of the sarcoma resulted in a “complete response,” meaning tumor destruction and disappearance, together with a healthy recovery. Results will be presented in at the Veterinary Cancer Society’s annual conference in Louisville, Kentucky, October 17 – 20, 2018.
Study investigators were also pleased that IsoPet® met all RadioGel™ design performance criteria. Post-treatment imaging and dosimetry provided confirmatory data addressing the principal questions previously raised by an FDA review panel, including:
- Near-uniform placement by injection and interstitial perfusion within the tumor without vascular clearance to normal organs and tissues
- Very high therapeutic ratios (radiation dose to the tumor relative to normal organs)
- Effective, highly localized, high-dose radiotherapy, and complete absence of adverse side-effects in critical normal tissues
This is sounding pretty incredible, I thought. I went over to their website to poke around some more. After all, I became a shareholder around 1:00 PM EST on 9/26/2018.
First of all, one of their partners is IsoTherapeutics Group, LLC. This is a radiopharmaceutical company that was founded back in 2005. Their scientists have received over 100 patents for developing chemistry and radiopharma formulations. Not a bad partner to have.
Then, I was drawn to the Washington State University listing. Again, I had to investigate this deeper and see if I could find a mention of RadioGel or IsoPet on their website. Once again, I find a page under “Clinical Studies” specifically talking about Yttrium-90 RadioGel from June 2017. There was also a “Grants and Contracts Awards Summary” PDF that mentioned the same stuff dating back to March 2015.
By this moment, I was already adding shares on the September 27th – 28th and a couple days in October. I’m excited.
Vivos Inc. has obtained an exclusive license to eight (8) patents related to RadioGel™ device technology for use in high-dose radiation therapy. The license was granted by *Battelle pursuant to an option between Battelle and Vivos announced in February 2011. The Agreement grants Vivos an exclusive license to make, have made, use and sell RadioGel™ as a device. Yttrium-90 is a well-established medical isotope with many applications in cancer treatment. The combination of insoluble Yttrium-90 particles and the polymer gel carrier offers physicians an opportunity to deliver a safe, effective treatment option at a low cost. (Source)
The Company’s shorter-term objective is to obtain regulatory approval for its brachytherapy products and to then commercialize those products. (Source)
Friday, October 5th, the stock was moving up nicely until George Sharp ($RDGL Advisor) Tweeted news about him becoming the next CEO of Guard Dog, Inc. ($GRDO). For whatever reason, some guys reportedly dumped 8.5 million shares. The price dropped to nearly $0.025 and went back green not long after. Perhaps because Mr. Sharp “set the record straight” by Tweeting again that he wears many hats and continues to be an Advisor to RDGL.
At the end of the trading day, RDGL filed an “RW” — “Request for Withdrawal of Registration Statement on Form S-1 and Pre-Effective Amendment No. 1 on Form S-1/A filed on March 10, 2017 and February 9, 2018, respectively”
While I can only speculate, I’m thinking quite confidently this happened because RDGL was able to secure far better financing and Monday (or soon after) could come with some additional sweet news.
Obviously you must decide whether you want to invest / gamble your own money. I’m not recommending anyone Buy, Hold, or Sell. I’ll worry about my money and you worry about yours. As always, I just wanted to share the sources to much of the due diligence as I found it.